From Name:
From Email:
To Name:
To Email:

Optional Message:


2018 Special Study on DCIS Breast Cancer (COMET) — pilot study opportunity

from ACS-CRP

Ductal Carcinoma in situ (DCIS), or stage 0 breast cancer, is diagnosed in over 50,000 women in the United States each year. Current NCCN guidelines dictate that DCIS be treated upon diagnosis with a combination of surgery, radiation, and hormonal therapy- treatments similar to those recommended to patients with invasive cancer. However, there is an emerging debate around whether “active surveillance” for DCIS may also be a safe and less morbid option in women with some subtypes of DCIS. A Commission on Cancer (CoC) Special Study will be launched in 2018 to investigate outcomes from DCIS treatment retrospectively. A pilot study will take place in the fall of 2017 with a small number of sites in an effort to garner feedback from registrars on data collection for patients with DCIS.

When the pilot study is completed participating sites will receive credit for Standard 4.7, Studies of Quality. This pilot study will also fulfill the requirements set forth by Standard 5.7 for Special Studies. Sites participating in the pilot study will not be required to participate again in the DCIS Special Study in 2018. Please email specialstudy@facs.org if you are interested in participating in the pilot study. Note that participation in the pilot study is not required. We will notify sites of the status of their participation by early July. Further information can be found on (website link). We look forward to working with you! more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063